Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Remarkable elevation of fibrinolysis markers and procalcitonin associated with dabrafenib plus trametinib combination therapy: Uncommon adverse events.

The Journal of dermatology - 1 Feb 2020

Nakamura Yoshiyuki, Ishizuki Shoichiro, Iwasaki Riko, Okiyama Naoko, Ishitsuka Yosuke, Matsumura Yutaka, Tanaka Ryota, Maruyama Hiroshi, Watanabe Rei, Fujisawa Yasuhiro

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Fibrinolysis
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Share to Skin Neoplasms

Source

Identifiers

PMID: 31762081
DOI: 10.1111/1346-8138.15163

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Remarkable elevation of fibrinolysis markers and procalcitonin associated with dabrafenib plus trametinib combination therapy: Uncommon adverse events.PMID 31762081Read ↗

Biomarker research and leading causes of death worldwide: a rather feeble relationshipSemantic proximity Read ↗

Real-World Data Analysis of Vascular and Lymphatic Adverse Events Associated with Anti-Tumor Angiogenesis Drugs: A WHO-VigiAccess StudySemantic proximity Read ↗

Management of Refractory Immune Thrombocytopenia with Fostamatinib: A Case ReportSemantic proximity Read ↗

Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin.Semantic proximity Read ↗

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read ↗

Tumor Lysis Syndrome in a Patient with BRAFV600E Mutated Colon Cancer Treated with Cetuximab and Encorafenib.Semantic proximity Read ↗

Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problemSemantic proximity Read ↗

Ruxolitinib withdrawal syndrome leading to tumor lysis.Semantic proximity Read ↗

Exploring the Association Between Upadacitinib and Venous Thromboembolism: An Integrated Analysis of Adverse Drug Events and Network Toxicology MechanismsSemantic proximity Read ↗

Dramatic response of acute disseminated intravascular coagulation to erlotinib in a patient with lung adenocarcinoma with activating EGFR mutation.Semantic proximity Read ↗

Systemic coagulation activation in patients with glioblastomaSemantic proximity Read ↗

Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.